Your search returned 5 results.

Results
	1.	The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. MedStar authors: Khan, Rozi PMID: 32383079 Year: 2021 Citation: Journal of Nuclear Cardiology. 28(6):2799-2807, 2021 12. Institution: MedStar Union Memorial Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Diep L, Doukky R, Iskander F, Iskander M, Kattoor AJ, Khan R, Kolkailah AA DOI: https://dx.doi.org/10.1007/s12350-020-02135-y Add to cart (remove)
	2.	Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi()). MedStar authors: Shara, Nawar M PMID: 23953278 Year: 2013 Citation: Journal of Foot & Ankle Surgery. 52(6):781-5, 2013 Nov-Dec. Institution: MedStar Health Research Institute Medline publication type: Case Reports Journal Article Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Attinger CE, Dunning DM, Hubley KJ, Kallakury B, McNish S, Shanmugam VK, Shara N, Steinberg JS DOI: http://dx.doi.org/10.1053/j.jfas.2013.07.003 Add to cart (remove)
	3.	The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. MedStar authors: Khan, Rozi PMID: 32632913 Year: 2022 Citation: Journal of Nuclear Cardiology. 29(1):101-110, 2022 Feb. Institution: MedStar Union Memorial Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Doukky R, Iskander F, Iskander M, Khan R, Kolkailah AA, Patel PP DOI: https://dx.doi.org/10.1007/s12350-020-02259-1 Add to cart (remove)
	4.	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. MedStar authors: Cruz, Allan-Louie PMID: 28453705 Year: 2017 Citation: Annals of Oncology. 28(5):1050-1056, 2017 May 01 Institution: MedStar Washington Hospital Center Department: Hematology/Oncology Medline publication type: Journal Article Form of publication: Journal Article All authors: Barr PM, Brander DM, Cheson BD, Claxton DF, Cruz AL, Daniel C, Fanning M, Foon K, Gashonia L, Goy A, Henick Bachow S, Hill BT, Howlett C, Isaac K, Kennard KH, Kiselev P, Lamanna N, Lenhart J, Mato AR, Nabhan C, Pu JJ, Schuster SJ, Skarbnik AP, Svoboda J, Timlin C, Ujjani CS, Winter AM, Yacur M, Zent CS DOI: https://dx.doi.org/10.1093/annonc/mdx031 Add to cart (remove)
	5.	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. MedStar authors: Trivedi, Neel PMID: 29610115 Year: 2018 Citation: Blood Advances. 2(7):762-768, 2018 Apr 10 Institution: MedStar Washington Hospital Center Department: Hematology and Oncology Medline publication type: Journal Article Form of publication: Journal Article All authors: Cheson BD, Khan N, Ramzi P, Skarbnik A, Trivedi N, Ujjani C, Wang H DOI: https://dx.doi.org/10.1182/bloodadvances.2017015263 Add to cart (remove)

Powered by Koha